Skip to menu Skip to content Skip to footer

Towards selective targeting of HDACs for anti-inflammatory applications (2009-2011)

Abstract

HDAC inhibitors are anti-cancer drugs that kill rapidly growing cells (like cancer cells). These drugs also have anti-inflammatory properties and so may be beneficial in chronic inflammatory diseases such as as Rheumatoid Arthritis. However, it is unknown how they reduce inflammation. In this project we aim to understand how HDAC inhibitors act as anti-inflammatory agents and to design new HDAC inhibitors with reduced side effects for the treatment of inflammatory diseases.

Experts

Professor Matt Sweet

Affiliate of The Centre for Cell Bi
Centre for Cell Biology of Chronic Disease
Institute for Molecular Bioscience
NHMRC Leadership Fellow - GL
Institute for Molecular Bioscience
Matt Sweet
Matt Sweet

Professor David Fairlie

Centre Director of The Centre for C
Centre for Chemistry and Drug Discovery
Institute for Molecular Bioscience
Affiliate of ARC COE for Innovation
ARC Centre of Excellence for Innovations in Peptide and Protein Science
Institute for Molecular Bioscience
Centre Director of Institute for Mo
Institute for Molecular Bioscience
NHMRC Leadership Fellow and Group L
Institute for Molecular Bioscience
David Fairlie
David Fairlie

Professor Allison Pettit

Professorial Research Fellow
Mater Research Institute-UQ
Faculty of Medicine
Allison Pettit
Allison Pettit

Dr Ian Ross

Senior Biologist
Institute for Molecular Bioscience
Ian Ross